carboplatin,etoposide,atezolizumab,tiragolumab
roche
['biomarker', 'skyscraper-02', 'sclc']
#asco22 lessons from neg skyscraper-02 in #sclc for the future: go to a ph3 only after solid ph1-2 data select patients on the base of molecular subtype increased activity in inflamed phenotype? pdl1 poor biomarker in sclc, translational res needed 
#MedicalOncologist MSc Transl Res Univ Paris Sud   #LungCancer biology, immunotherapy, clinical trials #LCSM @myESMO faculty #OncoAlert   live to give